NO20012169D0 - Forbindelser med veksthormonfrigjörende egenskaper - Google Patents

Forbindelser med veksthormonfrigjörende egenskaper

Info

Publication number
NO20012169D0
NO20012169D0 NO20012169A NO20012169A NO20012169D0 NO 20012169 D0 NO20012169 D0 NO 20012169D0 NO 20012169 A NO20012169 A NO 20012169A NO 20012169 A NO20012169 A NO 20012169A NO 20012169 D0 NO20012169 D0 NO 20012169D0
Authority
NO
Norway
Prior art keywords
growth hormone
compounds
hormone releasing
releasing properties
properties
Prior art date
Application number
NO20012169A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012169L (no
Inventor
Michael Ankersen
Lutz Stefan Richter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20012169L publication Critical patent/NO20012169L/no
Publication of NO20012169D0 publication Critical patent/NO20012169D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO20012169A 1998-11-03 2001-05-02 Forbindelser med veksthormonfrigjörende egenskaper NO20012169D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801414 1998-11-03
PCT/DK1999/000594 WO2000026252A1 (en) 1998-11-03 1999-11-03 Compounds with growth hormone releasing properties

Publications (2)

Publication Number Publication Date
NO20012169L NO20012169L (no) 2001-05-02
NO20012169D0 true NO20012169D0 (no) 2001-05-02

Family

ID=8104574

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012169A NO20012169D0 (no) 1998-11-03 2001-05-02 Forbindelser med veksthormonfrigjörende egenskaper

Country Status (16)

Country Link
EP (1) EP1127071B1 (ja)
JP (1) JP4481502B2 (ja)
KR (1) KR20010080388A (ja)
CN (1) CN1325408A (ja)
AT (1) ATE272651T1 (ja)
AU (1) AU1262800A (ja)
BR (1) BR9915009A (ja)
CA (1) CA2347102A1 (ja)
CZ (1) CZ20011309A3 (ja)
DE (1) DE69919195T2 (ja)
HU (1) HUP0104244A3 (ja)
IL (1) IL142579A0 (ja)
NO (1) NO20012169D0 (ja)
PL (1) PL347433A1 (ja)
WO (1) WO2000026252A1 (ja)
ZA (1) ZA200102997B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
WO2005097173A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869974B1 (en) * 1995-12-22 2009-03-04 Novo Nordisk A/S Compounds with growth hormone releasing properties

Also Published As

Publication number Publication date
DE69919195T2 (de) 2005-08-04
NO20012169L (no) 2001-05-02
CA2347102A1 (en) 2000-05-11
JP4481502B2 (ja) 2010-06-16
AU1262800A (en) 2000-05-22
IL142579A0 (en) 2002-03-10
JP2002528556A (ja) 2002-09-03
EP1127071B1 (en) 2004-08-04
WO2000026252A1 (en) 2000-05-11
ZA200102997B (en) 2001-11-19
CZ20011309A3 (cs) 2001-10-17
PL347433A1 (en) 2002-04-08
EP1127071A1 (en) 2001-08-29
HUP0104244A2 (hu) 2002-04-29
DE69919195D1 (de) 2004-09-09
ATE272651T1 (de) 2004-08-15
HUP0104244A3 (en) 2002-05-28
CN1325408A (zh) 2001-12-05
KR20010080388A (ko) 2001-08-22
BR9915009A (pt) 2001-08-07

Similar Documents

Publication Publication Date Title
CY1109626T1 (el) Ενωσεις με ιδιοτητες αποδεσμευσης αυξητικης ορμονης
IL129592A0 (en) 5-HT1f agonists
NO962664L (no) Forbindelser med veksthormonfrigjörende egenskaper
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
YU13301A (sh) Muskarinski agonisti i antagonisti
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
SE9802937D0 (sv) Novel compounds
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
TR200200278T2 (tr) Kalsilitik bileşimler
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
ID25478A (id) Agonis 5-ht1f
ATE470671T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь